31st March, 2021

To, The Deputy Manager Department of Corporate Services, BSE Ltd, PJ Towers Dalal Street, Mumbai-01 Scrip Code: 511509

Dear Sir/Madam,

Sub: Outcome of Board Meeting-Reg. Ref: Regulation 30 & other applicable regulations of SEBI (LODR) Regulations, 2015.

We wish to inform you that the Board of Directors of the Company, at their just concluded meeting *interalia* have transacted the following business:

 Allotment of 1,50,000 equity shares of Rs.10/- each at an issue price of Rs.45/-(premium of Rs.35/- each) on conversion of warrants issued on preferential basis to the following promoter group on receipt of the balance application money of Rs. 50,62,500/- (being the 75% of the issue price).

Post the aforesaid allotment, the paid up capital of the Company has increased to Rs. 13,41,95,200/-

Sl. No	Name of Allottees	Category	Number of Equity Shares allotted
1	Shri Shri Resorts Private Limited	Promoter Group	1,50,000
	Total		1,50,000

 Based on the recommendation of the Nomination & Remuneration Committee the Board of Directors have appointed Dr. Karopadi Shivanand Nayak (DIN: 03523002) as an Additional Director and as a Non-Executive Non-Independent Director of the Company with effect from 1st April, 2021 subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.

Further, in accordance with the circular dated 20th June, 2018, issued by the Stock Exchanges, he is not debarred from holding office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

A Kathik HYDERABAD

Registered Office : # 8-2-672/5&6, Ilyas Mohanmmed Khan Estate, 3rd Floor, Road No-1, Banjarahills, Hyderabad, India -500034. Address of Preclinical Research Facility : Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email : investors@vivobio.com, Phone : 040-23313288, Website : www.vivobio.com, CIN : L65993TG1987PLC007163. 3. Authorisation under regulation 30 (5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the contact details of the Key Managerial Personnel ("KMP") who have been severally authorized by Board of Directors of the Company, for the purpose of determining materiality of an event or information to the Stock Exchanges from time to time under the said regulation is as follows:

Name of the KMP	Designation	Contact Details
Mr. M. Kalyan Ram	Whole Time Director	investors@vivobio.com 040-2331 3288
Mr. K.T.V. Kaladhar	Whole Time Director & CFO	accounts@vivobio.com 040-2331 3288
Mr. A. Karthik		karthik@vivobio.com 040-2331 3288

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD|CMD|4|1015 dated 09th September 2015; including the brief profile of the above Director is enclosed in **Annexure-A** to this letter.

A copy of this letter is being hosted on the Company's website at <u>www.vivobio.com</u>.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For Vivo Bio Tech Ltd

Kathik

A.Karthik Company Secretary



Vivo Bio Tech Ltd. Your Drug Discovery Partner

Annexure-A

Details of Dr. Karopadi Shivanand Nayak

Sl. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Dr. Karopadi Shivanand Nayak (DIN:03523002) as an Additional Director and as a Non-Executive Non- Independent Director of the Company.
2.	Date of appointment/eessation (as applicable) & term of appointment;	Appointment with effect from 1 st April, 2021 subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting.
3.	Brief profile (in case of appointment);	He is a pioneer in the field of Peritoneal Dialysis (PD) internationally and Cadaver Kidney Transplantation and well known in the areas of Nutrition in CKD with special interest in Ketoanalogues, Pre-Probiotics, Anaemia management in CKD, Acute Kidney Injury (AKI), Chronic Kidney Disease Management, Critical Care Nephrology including CRRT, Liver Dialysis (MARS & FPSA; Prometheus: Largest series in India). He was responsible for the Country's first Simultaneous Heart and Kidney Transplantation (SHK). He is also an internationally acknowledged expert in Telemedicine in Dialysis, Reverse 'Medical' Innovation & Medical Tourism.
4.	Qualifications	M.B.B.S, M.D.
5.	Disclosure of relationships between directors (in case of appointment of a director).	None of the Directors/ Key Managerial Personnel of the Company/ their relatives are in any way related or interested, financially or otherwise.



Registered Office : # 8-2-672/5&6, Ilyas Mohanmmed Khan Estate, 3rd Floor, Road No-1, Banjarahills, Hyderabad, India -500034. Address of Preclinical Research Facility : Sy.No:349/A, Pregnapur Village, Gajwel Mandal, Siddipet District, Telangana, India, Pin Code: 502311 Email : investors@vivobio.com, Phone : 040-23313288, Website : www.vivobio.com, CIN : L65993TG1987PLC007163.